Enthera Pharmaceuticals (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Enthera Pharmaceuticals

First-in-class therapeutics for autoimmune disorders

Founded 2016 Italy

Italy 21 employees Series A Total: $39.00M Biotechnology, Health Care +2

Enthera, a biotechnology startup founded in 2016 and headquartered in Italy, is making waves with its groundbreaking approach to treating autoimmune disorders. With the slogan "First-in-class therapeutics for autoimmune disorders," Enthera is focused on developing first-in-class biologics for underserved autoimmune conditions. Their therapeutic approach is designed to preserve and re-establish organ cell function, revolutionizing the treatment paradigm for intractable autoimmune diseases. Enthera recently secured a significant milestone with a €7.00M Series A investment on 28 January 2021, with funding coming from the prestigious Roche Venture Fund. This investment not only provides Enthera with substantial financial support but also signifies an acknowledgment of the potential impact of their innovative approach from a respected player in the pharmaceutical industry. The industries Enthera operates in include Biotechnology, Health Care, and Pharmaceuticals, reflecting the high growth potential and significance of their work. With their recent funding, Enthera is poised to make significant strides in advancing their therapeutic candidates and potentially reshaping the landscape of autoimmune disorder treatment. Enthera's innovative approach, combined with the backing of a leading investor, positions the company as an exciting prospect in the biotechnology and pharmaceutical sectors. As they continue to progress, Enthera's efforts have the potential to not only address unmet medical needs but also generate substantial value for their investors.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	••••••	1		28 Jan 2021
Series A	••••••	6	•••• ••••	28 Jul 2020
Seed Round	••••••	1		25 Jul 2018

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

••••••

28 Jan 2021

Series A

••••••

•••• ••••

28 Jul 2020

Seed Round

••••••

25 Jul 2018

FAQ About Enthera Pharmaceuticals

First-in-class therapeutics for autoimmune disorders

Enthera Pharmaceuticals was founded in 2016.

Enthera Pharmaceuticals is headquartered in Italy.

Enthera Pharmaceuticals operates in the following industries: Biotechnology, Health Care, Life Sciences, Pharmaceutical.

Enthera Pharmaceuticals has approximately 21 employees.

Enthera Pharmaceuticals has completed 3 funding rounds, raising a total of $39.00M. The latest funding stage is Series A.

Top alternatives and competitors to Enthera Pharmaceuticals include Moleculera Biosciences, IpiNovyx Bio, Annexon Biosciences, Kronus Inc, Xanthus Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Enthera Pharmaceuticals and Moleculera Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Enthera Pharmaceuticals

General Information

Track Enthera Pharmaceuticals

Discover More

About Enthera Pharmaceuticals

Funding Rounds & Investors (3)

Enthera Pharmaceuticals Alternatives & Competitors

FAQ About Enthera Pharmaceuticals

Don't just browse. Track.